secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001104659-23-038073
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone reports FY2022 operating loss of $58.4M; NDA for etripamil on track for Q3 2023
--------------------------------------------------------------------------------

- Cash, equivalents, and short-term investments of $64.6M as of Dec 31, 2022; plus $50M from March 2023 private placement expected to fund into mid-2025.
- NDA submission for etripamil nasal spray in PSVT expected in Q3 2023; Phase 3 RAPID trial met primary endpoint (64.3% conversion vs 31.2% placebo).
- Entered $125M strategic financing with RTW Investments: $50M convertible notes and $75M synthetic royalty commitment post-FDA approval.
- Seth H.Z. Fischer appointed to Board of Directors effective March 21, 2023; brings commercial expertise from Johnson & Johnson and Vivus.
- Full year 2022 operating loss of $58.4M vs $42.9M in 2021; R&D expense $39.8M, G&A $15.7M, commercial $9.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923038073/0001104659-23-038073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923038073/tm2310783d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-038073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer